Primary Record
Abiraterone
- In stock
- 2,348 g
- Purity
- 98.8 %
- CAS
- 154229-19-3
Compound Identifiers & Properties
- CAS
- 154229-19-3
- PubChem CID
- 132971
- SMILES
- C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
- Canonical SMILES
- C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
Names & Synonyms
- Abiraterone
- 154229-19-3
- Abiraterona
- Zytiga
- abirateronum
- Abirateron;
- CB 7598
- CB-7598
- Abiraterone (CB-7598)
- Abiraterone [INN:BAN]
- Abiraterone (Standard)
- RefChem:57133
- 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
- Abiraterone/CB-7598
- ABIRATERONE [MI]
- ABIRATERONE [INN]
- CB7598
- D02STN
- ABIRATERONE [VANDF]
- (3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol
- Abiraterone (AR inhibitor)
- Abiraterone - CB-7598
- AC1L31XF
- C24H31NO
- CHEMBL254328
- CB 7630 [as acetate]
- MFCD00924100
- SCHEMBL61108
- ABIRATERONE [WHO-DD]
- UNII-G819A456D0
- cc-239
- CHEBI:68642
- MLS006010235
- US9487554, Abiraterone
- DTXSID80879993
- GTPL6745
- orb1300971
- Abiraterone - Bio-X trade mark
- G819A456D0
- NSC-741232
- SCHEMBL29359971
- 154229-19-3 (Abiraterone)
- BDBM25458
- CTK8B7779
- EX-A106
- L02BX03
- QCR-150
- GZOSMCIZMLWJML-VJLLXTKPSA-N
- ABIRATERONE [USP IMPURITY]
- DTXCID501021626
- GLXC-07971
- AMX10150
- C24-H31-N-O
- ZINC3797541
- Abiraterone(CB-7598)/CB7598
- ABP000222
- AN-849
- ANW-58538
- CID132971
- EBC-13814
- HY-70013R
- NSC749226
- s1123
- 17-(pyridin-3-yl)androsta-5,16-dien-3beta-ol
- AKOS005146525
- ACN-028791
- AM84498
- CID:132971
- CS-0156
- DB05812
- ES-0045
- FA16899
- NSC 741232
- NSC-749226
- RL01978
- US9611270, Example 5, abiraterone
- (3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol
- AC-25764
- AJ-45637
- BA164060
- BC685739
- CJ-10764
- HY-70013
- SC-26224
- SMR002530050
- SID:210024022
- AB0031795
- J617.457D
- ST2407991
- TC-071424
- 17-(3-Pyridyl)androsta-5,16-dien-3.beta.-ol
- A2868
- A4240
- Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3beta)-
- FT-0657576
- X5008
- (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
- 17-(pyridin-3-yl)androsta-5,16-dien-3-ol
- 17-(3-pyridyl)androsta-5,16-dien-3-beta-ol
- 17-(3-Pyridyl)androsta-5.16-dien-3beta-ol
- A24884
- Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3b)-
- EN300-311691
- S-7705
- 17-(3-Pyridinyl)androsta-5,16-dien-3beta-ol
- AB01274738-01
- AB01274738_02
- (3-beta)-17-(3-Pyridinyl)-androsta-5,16-dien-3-ol
- 229A193
- C089740
- F222701
- Q321431
- SR-01000941584
- (3b)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol
- (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
- 3beta-Hydroxy-17-(3-pyridyl)-androsta-5,16-diene
- SR-01000941584-1
- (3-beta)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol
- (3|_)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol
- BRD-K50071428-001-01-7
- BRD-K50071428-001-03-3
- 3beta-Hydroxy-17-(pyridine-3-yl)androsta-5,16-diene
- Z2301684603
- 17-(PYRIDIN-3-YL)ANDROSTA-5,16-DIEN-3.BETA.-OL
- B0084-059670
- Zytiga; (3b)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol
- (1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-ol
- Abiraterone/(3|A)-17-(Pyridin-3-yl)-androsta-5,16-dien-3-ol
- ANDROSTA-5,16-DIEN-3-OL, 17-(3-PYRIDINYL)-(3.BETA.)-
- (3aS,3bR,7S,9aR,9bS,11aS)-9a,11a-dimethyl-1-(pyridin-3-yl)-3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-ol
- (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(3-pyridyl)-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
- (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol.
- (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta(a)phenanthren-3-ol
- Abiraterone; CB 7598; (3beta)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol; 17-(3-Pyridinyl)-androsta-5,16-dien-3beta-ol
- ABT
- AER